Sarepta Therapeutics Inc (SRPT)
109.11
-3.37
(-3.00%)
USD |
NASDAQ |
Nov 14, 16:00
109.45
+0.34
(+0.31%)
After-Hours: 07:00
Sarepta Therapeutics Free Cash Flow (Quarterly): -107.96M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -107.96M |
| June 30, 2024 | -14.22M |
| March 31, 2024 | -284.52M |
| December 31, 2023 | -73.70M |
| September 30, 2023 | -155.48M |
| June 30, 2023 | -140.19M |
| March 31, 2023 | -218.98M |
| December 31, 2022 | -100.56M |
| September 30, 2022 | -74.42M |
| June 30, 2022 | -75.89M |
| March 31, 2022 | -106.73M |
| December 31, 2021 | -33.84M |
| September 30, 2021 | -133.57M |
| June 30, 2021 | -115.04M |
| March 31, 2021 | -201.52M |
| December 31, 2020 | -203.14M |
| September 30, 2020 | -263.49M |
| June 30, 2020 | -126.77M |
| March 31, 2020 | 618.67M |
| December 31, 2019 | -181.05M |
| September 30, 2019 | -76.86M |
| June 30, 2019 | -95.69M |
| March 31, 2019 | -162.50M |
| December 31, 2018 | -139.99M |
| September 30, 2018 | -134.49M |
| Date | Value |
|---|---|
| June 30, 2018 | -126.83M |
| March 31, 2018 | -48.51M |
| December 31, 2017 | -35.58M |
| September 30, 2017 | -65.66M |
| June 30, 2017 | -88.37M |
| March 31, 2017 | -63.60M |
| December 31, 2016 | -84.58M |
| September 30, 2016 | -61.78M |
| June 30, 2016 | -44.06M |
| March 31, 2016 | -62.27M |
| December 31, 2015 | -32.81M |
| September 30, 2015 | -47.80M |
| June 30, 2015 | -29.42M |
| March 31, 2015 | -44.27M |
| December 31, 2014 | -28.91M |
| September 30, 2014 | -48.22M |
| June 30, 2014 | -44.35M |
| March 31, 2014 | -33.88M |
| December 31, 2013 | -18.55M |
| September 30, 2013 | -21.56M |
| June 30, 2013 | -12.90M |
| March 31, 2013 | -15.46M |
| December 31, 2012 | -7.581M |
| September 30, 2012 | -7.886M |
| June 30, 2012 | -6.061M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-284.52M
Minimum
Mar 2024
618.67M
Maximum
Mar 2020
-99.62M
Average
-120.91M
Median
Free Cash Flow (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 72.61M |
| Vertex Pharmaceuticals Inc | 1.302B |
| Alnylam Pharmaceuticals Inc | 39.52M |
| Biomarin Pharmaceutical Inc | 200.30M |
| Cytokinetics Inc | -102.20M |